螨过敏性哮喘患儿标准化特异性免疫治疗3年的有效性观察

李羚; 惠郁; 钱俊; 郭赟; 张锡莲; 张晓娟

doi:10.7499/j.issn.1008-8830.2013.05.012

PDF(941 KB)

中国当代儿科杂志 ›› 2013, Vol. 15 ›› Issue (5) : 368-371. DOI: 10.7499/j.issn.1008-8830.2013.05.012

论著·临床研究

螨过敏性哮喘患儿标准化特异性免疫治疗3年的有效性观察

李羚，惠郁，钱俊，郭赟，张锡莲，张晓娟

作者信息 +

Therapeutic efficacy of 3-year subcutaneous immunotherapy in asthmatic children allergic to mite

LI Ling, HUI Yu, QIAN Jun, GUO Yun, ZHANG Xi-Lian, ZHANG Xiao-Juan

Author information +

文章历史 +

摘要

目的：评价皮下注射免疫治疗（SCIT）3年对螨过敏性哮喘患儿的有效性。方法：选择对屋尘螨过敏的哮喘（伴或不伴有过敏性鼻炎）患儿90例（5~14岁），随机分成SCIT联合哮喘规范化治疗组（n=45）与仅哮喘规范化治疗的对照组（n=45），观察两组患儿3年治疗中的症状评分、吸入激素的用量、皮肤变应原点刺试验结果、最大呼气流速、血清总IgE的变化。结果：SCIT治疗组和对照组治疗第1、2、3年的日、夜间症状评分均较其基线期明显下降（P<0.01），且随着治疗时间的延长而逐年下降（P<0.01）。SCIT治疗组、对照组治疗第1、2、3年吸入激素剂量均明显低于其基线期（P<0.01），且随着治疗时间的延长而逐年下降（P<0.01）。治疗组吸入激素平均剂量于第2年、第3年均低于对照组（P<0.05）。3年治疗结束后，因症状缓解而停止吸入激素比例SCIT治疗组较对照组高（29% vs 20%，P<0.05）。第3年末SCIT治疗组血清总IgE水平较其基线期明显下降（P<0.01），亦明显低于对照组（P<0.05）。结论：SCIT治疗对于过敏性哮喘患儿是有效的，并可减少吸入性激素的用量。

Abstract

OBJECTIVE: To evaluate the therapeutic efficacy of 3-year subcutaneous immunotherapy (SCIT) in asthmatic children allergic to mite. METHODS: Ninety asthmatic children allergic to house dust mite (with or without allergic rhinitis) and aged 5-14 years were randomized into SCIT treatment group (n=45) and control group (n=45). The SCIT treatment group received SCIT combined with standardized treatment for asthma, while the control group received the standardized treatment alone. The therapeutic effects were assessed based on the daytime and nighttime symptom scores, mean daily doses of inhaled corticosteroids (ICS), skin prick test results, peak expiratory flows and total serum IgE at baseline and in the 3-year treatment. RESULTS: In both groups, the daytime and nighttime symptom scores in the first, second, and third years of treatment were significantly lower than the baseline values (P<0.01), and the scores decreased year by year during the 3-year treatment (P<0.01). Also, the mean daily doses of ICS in the first, second, and third years of treatment were significantly lower than the baseline values (P<0.01), and the doses decreased year by year during the 3-year treatment (P<0.01). The mean daily dose was significantly lower in the SCIT treatment group than in the control group in the second and third years of treatment (P<0.05). After 3-year treatment, the SCIT treatment group had a significantly higher proportion of children who discontinued use of ICS due to remission of symptoms compared with the control group (29% vs 20%, P<0.05). At the end of the 3-year treatment, the total serum IgE was significantly lower than the baseline value in the SCIT treatment group (P<0.01), and it was significantly lower in the SCIT treatment group than in the control group (P<0.05). CONCLUSIONS: Three-year SCIT is effective in asthmatic children allergic to house dust mite and allows reduction in the dosage of ICS.

导出引用

李羚，惠郁，钱俊，郭赟，张锡莲，张晓娟. 螨过敏性哮喘患儿标准化特异性免疫治疗3年的有效性观察[J]. 中国当代儿科杂志. 2013, 15(5): 368-371 https://doi.org/10.7499/j.issn.1008-8830.2013.05.012

LI Ling, HUI Yu, QIAN Jun, GUO Yun, ZHANG Xi-Lian, ZHANG Xiao-Juan. Therapeutic efficacy of 3-year subcutaneous immunotherapy in asthmatic children allergic to mite[J]. Chinese Journal of Contemporary Pediatrics. 2013, 15(5): 368-371 https://doi.org/10.7499/j.issn.1008-8830.2013.05.012

参考文献

［1］Eifan AO, Akkoc T, Yildiz A, Keles S, Ozdemir C, Bahceciler NN, et al. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial［J］. Clin Exp Allergy, 2010, 40(6): 922-932.

［2］Blumberga G, Groes L, Dahl R. SQ-standardized house dust mite immunotherapy as an immunomodulatory treatment in patients with asthma［J］. Allergy, 2011, 66(2):178-185.

［3］中华医学会儿科学分会呼吸学组，中华医学会《中华儿科杂志》编辑委员会. 儿童支气管哮喘防治常规（试行）［J］. 中华儿科杂志,2004,42(2):100-106.

［4］Basomba A, Tabar AI, de Rojas DH, Garcia BE, Alamar R, Olaguibel JM, et al. Allergen vaccination with a liposomeencapsulated extract of Dermatophagoides pteronyssinus: a randomized, double-blind, placebo-controlled trial in asthmatic patients［J］. J Allergy Clin Immunol, 2002, 109(6): 943-948.

［5］Klimek L, Mewes T, Wolf H, Hansen I, Schnitker J, Mann WJ. The effects of short-term immunotherapy using molecular standardized grass and rye allergens compared with symptomatic drug treatment on rhinoconjunctivitis symptoms, skin sensitivity, and specific nasal reactivity［J］. Otolaryngol Head Neck Surg, 2005, 133(4): 538-543.

［6］谭永强, 曹兰芳, 沈瑾, 陈柳, 叶桂云, 徐决平. 粉尘螨特异性免疫治疗联合规范化防治在哮喘控制中的作用［J］. 实用儿科临床杂志，2011，26（4）：241-243.

［7］Creticos PS. The consideration of immunotherapy in the treatment of allergic asthma［J］. J Allergy Clin Immunol, 2000, 105(2): 559-575.

［8］Cox L, Cohn JR. Duration of allergen immunotherapy in respiratory allergy: when is enough, enough?［J］. Ann Allergy Asthma Immunol, 2007, 98(5): 416-426.

［9］黄娅娜, 黄英, 代继宏, 杨方方. 哮喘儿童中止皮下特异性免疫治疗原因分析［J］.中国当代儿科杂志，2012,14（9）:671-674.

［10］Frew AJ. Immunotherapy of allergic disease［J］. J Allergy Clin Immunol, 2003, 111(2 Suppl): S712-S719.

［11］Mellerup MT, Hahn GW, Poulsen LK, Malling H. Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic sideeffects during induction treatment［J］. Clin Exp Allergy, 2000, 30(10): 1423-1429.